Pro-Dex, Inc. (PDEX) Fair Value 2026

PDEX · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.8 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Pro-Dex, Inc. (PDEX) trades at $62.55, versus a $51.10 median fair value across its 10 active models — 18.3% below the current price. QOC: 7.8/10. Value Trap Risk: 30/100 (LOW). 10/13 models active. Within that set, the Bayesian DCF component alone returns $2.82.

Key Facts

Ticker
PDEX
Price
$62.55
Quality Score
7.8/10
Value Trap Risk
30/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +26.3% upside with 62% confidence
Risk: Majority of models suggest overvaluation

Is Pro-Dex, Inc. (PDEX) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Pro-Dex, Inc. (PDEX) appears overvalued as of : the median of 10 independent fair value estimates is $51.10, 18.3% below the current price of $62.55. Estimates range from $2.82 to $96.92. PDEX scores 7.8/10 on fundamental quality and 30/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. PDEX’s -18.3% gap is narrower than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Pro-Dex, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PDEX?

10 Intrinsic Value Models vs. Current Price ($62.55)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $2.82 -95.5%
Intrinsic · High Conviction
 $27.75 -55.6%
Ensemble · Low Conviction
 $43.35 -30.7%
Scenario · High Conviction
 $79.02 +26.3%
Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is PDEX's Fair Value Range?

Spread across 10 independent models · $2.82 to $96.92

CirclFi's 10 active models place Pro-Dex, Inc. (PDEX) between $2.82 and $96.92 per share, a spread of 184% of the median. The median of that range — $51.10 — is the fair value CirclFi publishes for PDEX, against a current price of $62.55.

Low · Bayesian DCFHigh · ML-RIV
$2.82median $51.10$96.92
Where the range comes from
Most bearish modelBayesian DCF$2.82
Most bullish modelML Residual Income$96.92
Model agreement3 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PDEX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PDEX, not a CirclFi price target. How each model works →

What Is Pro-Dex, Inc. (PDEX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Pro-Dex, Inc. at its current price of $62.56. The median intrinsic value is estimated at $51.10 (-18.3% vs price), with 6 models flagging overvaluation risk. Model dispersion is worth noting: ML-RIV targets $96.92 (+54.9%), versus Bayesian DCF at $2.82 (-95.5%). This +150.4% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About PDEX?

10 of 13 models are currently active for PDEX. Of these, 3 models suggest upside while 7 models suggest overvaluation. Taken together, their median fair value for PDEX is $51.10 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $2.82 on its own, implying -95.5% downside from the current price. See which stocks rank higher →

How Does PDEX Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, PDEX ranks #15 by Quality of Company score. CirclFi's QOC score of 7.8/10 evaluates 32 fundamental signals. A score of 7.8 indicates above-average quality.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Pro-Dex, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is PDEX a Value Trap?

CirclFi's Value Trap algorithm assigns PDEX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Pro-Dex, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Pro-Dex, Inc.'s fundamental quality profile registers 7.8/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +150.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PDEX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PDEX's 10 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pro-Dex, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

10 related Medical Instruments & Supplies stocks with 13-model coverage

EMBCEmbecta Corp.QOC 7.8ATRCAtriCure, Inc.QOC 7.8RGENRepligen CorporationQOC 8.0STVNStevanato Group S.p.A.QOC 7.7UTMDUtah Medical Products, Inc.QOC 8.2MDLNMedline Inc.QOC 7.7AVTRAvantor, Inc.QOC 6.5CUPRCuprina Holdings (Cayman) LimitedQOC 5.6ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: EMBC · ATRC · RGEN · STVN · UTMD · MDLN · AVTR · CUPR · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to PDEX?

7 companies across all industries closest to PDEX’s Quality of Company score of 7.8/10.

EMNEastman Chemical CompanyQOC 7.8NINiSource Inc.QOC 7.8APOGApogee Enterprises, Inc.QOC 7.8SWSmurfit Westrock PlcQOC 7.8MFCManulife Financial CorporationQOC 7.8PBProsperity Bancshares, Inc.QOC 7.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: EMN · NI · APOG · SW · MFC · PB · NVDA

Where Does PDEX Sit in CirclFi's Medical Instruments & Supplies Rankings?

PDEX is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Pro-Dex, Inc.’s Valuation?

What is Pro-Dex, Inc.'s intrinsic value in 2026?

CirclFi puts Pro-Dex, Inc. (PDEX)'s intrinsic value at $51.10 — the median of 10 independent model estimates as of 2026-08-28, ranging from $2.82 to $96.92. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $2.82 on its own. The Quality of Company score is 7.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PDEX overvalued or undervalued right now?

At $62.55, 3 of 10 active models suggest PDEX may be undervalued, while 7 indicate potential overvaluation. The median of all 10 fair value estimates is $51.10, 18.3% below the current price of $62.55 — a consensus view that PDEX is overvalued. The assessment depends on which methodology best fits Pro-Dex, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 7.8 mean for PDEX?

Pro-Dex, Inc.'s QOC of 7.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on PDEX?

CirclFi analyzes PDEX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PDEX?

Of the 10 models currently active on PDEX, ML Residual Income is the most bullish at $96.92 per share, and Bayesian DCF is the most bearish at $2.82. CirclFi's published fair value for PDEX is the median of that range, $51.10, not either extreme. The gap between the two ends equals 184% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PDEX a value trap in 2026?

Pro-Dex, Inc.'s Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Pro-Dex, Inc. (PDEX) has a median fair value of $51.10 — 18.3% below the current price of $62.55 — as of 2026-08-28.” Source: circlfi.com/stock/PDEX/ · Methodology
Primary sources for this PDEX valuation
  • Financial statements: Pro-Dex, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000788920) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PDEX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on PDEX.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for PDEX Unlock All 10 — $39/mo